Sales veteran to lead next phase of growth for carrier-grade open, disaggregated networking
Santa Clara, CA – December 15, 2025 – IP Infusion, a global leader in open networking software solutions, announced today that Tom Savoie has been appointed Chief Executive Officer. Savoie has held senior leadership roles at IP Infusion, including Chief Sales Officer, and brings nearly three decades of experience across telecom operators, network equipment manufacturers, and networking software companies.
Savoie has worked on both the operator and vendor sides of the market, helping customers transition from proprietary systems to open, virtualized, and disaggregated networks. He joined IP Infusion in an entry-level contributor sales position and, over the past 16 years, has been instrumental in most of the company's largest sales. His prior roles include leadership positions at Nortel and Wind River Systems/Intel, where he focused on white box platforms, network operating systems, and software-defined networking and NFV solutions.
"From my vantage point, IP Infusion is where operators around the world come when they are ready to take disaggregation from pilot to production," said Tom Savoie, CEO of IP Infusion. "That work is only becoming more important as our customers scale for 5G, AI workloads, and cloud connectivity. I look forward to supporting our company's important mission to give operators a carrier-grade alternative to legacy networking stacks so they can choose their hardware and reduce total cost of ownership without sacrificing performance or reliability."
"Tom combines deep technical understanding with frontline commercial experience in open networking," said Kiyo Oishi, President and CEO of ACCESS CO., LTD., the parent company of IP Infusion. "ACCESS sees IP Infusion as a strategic growth engine in our network business. Under Tom's leadership, we expect the company to expand its global footprint and accelerate innovation in disaggregated network operating systems."
With more than 600 customers and tens of thousands of carrier deployments, IP Infusion's OcNOS® network operating system powers open, disaggregated access, aggregation, transport, and data center networks on white box hardware for carriers, network equipment manufacturers, and enterprise data centers worldwide.
Chi è IP Infusion
IP Infusion develops open network software solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion leads the market in Network Operating Systems. Its flagship platform, OcNOS®, empowers network operators to disaggregate their networks, streamline operations, and reduce total cost of ownership (TCO). Headquartered in Santa Clara, Calif., IP Infusion is a wholly owned subsidiary of ACCESS CO., LTD. For more information, visit www.ipinfusion.com/.
Media Contact:
Katherine Verducci, 1903 PR
kverducci@1903pr.com
408.429.5779
Chi è IP Infusion
IP Infusion è un fornitore leader di software di open networking e offre OcNOS, un sistema operativo di rete carrier-grade per service provider, data center e reti fabric AI. Con esperienza nel networking dal 1999 e oltre 600 operatori nel mondo, IP Infusion abilita un'infrastruttura di rete aperta, multi-vendor, efficiente nei costi e flessibile su hardware aperto validato di partner come Edgecore Networks, UfiSpace e Celestica. IP Infusion è una controllata al 100% di ACCESS CO., LTD. (Borsa di Tokyo: 4813).
Contatto stampa
For press inquiries, analyst briefings, or media materials, please contatti il nostro team or email pr@ipinfusion.com.
Dichiarazioni previsionali
Questo comunicato può contenere dichiarazioni previsionali relative a prodotti, tecnologie e piani di IP Infusion. Le dichiarazioni previsionali si basano sulle informazioni disponibili alla data di pubblicazione e comportano rischi e incertezze. I risultati effettivi possono differire. Piani di prodotto, funzionalità, tempistiche di rilascio e disponibilità sono soggetti a modifiche senza preavviso e non costituiscono un impegno, una promessa o un obbligo legale. IP Infusion non assume alcun obbligo di aggiornare le dichiarazioni previsionali.